Program

IN-DEPTH CONFERENCES

Rather than revisiting published data, invited experts are encouraged to share actionable insights, implementation strategies, and real-world experience in addressing the scientific, technological, regulatory, and financial challenges shaping the future of advanced therapies.

Through three high-level scientific sessions and a competitive plenary abstract session, Innovative Therapies Days fosters forward-looking discussions at the intersection of discovery, industrialization, and clinical deployment.

THURSDAY, OCTOBER 8TH

08:30 09:00

REGISTRATION AND WELCOME COFFEE

09:00 09:10

WELCOME ADRESS

Renaud Gaudillière, PMT director

09:10 10:00

OPENING KEYNOTES : THE STATE OF ADVANCED THERAPIES

09:10 09:40

Standing on Shoulders, Shaping the Future: The Journey of Cell Therapies

Pierre Tiberghien, EFS & International Society of Blood Transfusion, Besançon, FRA

09:40 10:00

Market Dynamics

Gavin Vuddamalay, Mabdesign, Paris, FRA

10:00 12:15

SESSION #1 ENGINEERING THE NEXT WAVE: Beyond the First CAR-T Generations CAR-T, In Vivo Strategies, Manufacturing & Global Access

Chairpersons : Christophe Ferrand and Marina Deschamps, Right Institute, Besançon, FRA

10:00 10:30

Next-Generation CAR-T / TCR Strategies for Solid Tumors

Naomi Taylor, Center for Cancer Research, Bethesda, USA

10:30 10:35

Industry Spotlight – Gold Sponsor

10:35 11:15

BREAK – EXHIBITION HALL

11:15 11:45

Engineering T cells and Manufacturing multiple ATPMs: multilayered challenges and opportunities

Jean-Sébastien Delisle, Centre of excellence in cell therapy, Hôpital Maisonneuve-Rosemont and Université de Montréal, Montreal, CAN

11:45 12:15

Expanding Access to CAR-T Therapies: Middle East & Asia Perspectives

Syed Osman Ahmed, King Faisal Specialist Hospital and Research Center, Riyad, SAU

12:15 14:00

LUNCH & EXHIBITION HALL

Simultaneous B2B meeting

14:15 14:45

SYMPOSIUM PLATINUM EXHIBITOR

14:45 17:30

SESSION #2 CAN REGENERATIVE MEDICINE BECOME INDUSTRIAL REALITY? Stem Cells : Manufacturing, Automation & the Path to Industrial Scale

Chairpersons : John De Vos, CHU Montpellier and Sylvain Perruche, Temis Santé, FRA

14:45 15:15

Pioneer Stem Cell Therapies: From Scientific Vision to Clinical Reality

Masayo Takahashi, VCCT Inc., Kobe, JAP

15:15 15:45

Pluripotent stem cells manufacturing for making and repairing human hearts

Robert Zweigerdt, Hannover Medical School, Hannover, GER

15:45 15:50

Industry Spotlight – Gold Sponsor

15:50 16:30

BREAK – EXHIBITION HALL

16:30 17:00

Clinical Opportunities, Early Clinical Experience and Future Prospects

Jeffrey Bluestone, Diabetes Center, University of California San Francisco, San Francisco, USA

17:00 17:30

Digital Twins for Cell Therapy Manufacturing: The GENESIS Perspective

Laura Guyot, Dassault Systems, Biot, FRA

17:30

AI-Driven Quality Control for Stem Cell Manufacturing and Organoid Platforms

Corinne Hoesli, McGill University, Montreal, CAN

17:45 18:45

OFFICIAL DELEGATION TOUR OF THE EXHIBITOR VILLAGE

17:45 22:00

POSTER'S SESSION & NETWORKING COCKTAIL – EXHIBITION HALL

FRIDAY, OCTOBER 9TH

08:15 08:30

WELCOME COFFEE

08:30 09:00

OPENING KEYNOTES

ATMP Development Support: Lessons from the ANSM Guidance Office

Guillaume Vaquer, French National Agency for Medicines and Health Products Safety, Paris, FRA

09:00 12:15

SESSION #3 WHAT COMES AFTER CELLS? Extracellular Vesicles, Cell-Free Therapies & Enabling Technologies

Chairpersons : Jérémy Magalon, AP-HM and Céline Elie-Caille, Femto-ST, FRA

09:00 09:30

Clinical Potential of MSC-EVs and Translational Challenges

Bernd Giebel, University of Duisburg-Essen, Essen, GER

09:30 10:00

Fibrinolytic Extracellular Vesicles: From Biology to a New Class of Thrombolytic Agents

Romaric Lacroix, AMU & Inserm 1263, Aix-Marseille, FRA

10:00 10:05

Industry Spotlight – Gold Sponsor

10:05 10:45

BREAK – EXHIBITION HALL

10:45 11:15

Engineering Extracellular Vesicles for RNA Therapeutic Delivery

Florence Gazeau, UMR 7057 CNRS – Université Paris Cité, Paris, FRA

11:15 11:45

Regulatory Status of EVs in Europe

Mathieu Guerriaud, CREDIMI University of Burgundy, Dijon, FRA

11:45 12:15

Microtechnologies Enabling Advanced Therapies

Maxime Adamczewski, BioIMP consortium, Besançon, FRA

12:15 14:00

LUNCH & Exhibition Hall

Simultaneous B2B meeting

14:00 15:30

SESSION #4 Emerging Innovations in Advanced Therapies

6 outstanding projects selected from submitted abstracts by the ITD Scientific Committee